Drug Target Review

NOVEMBER 17, 2023

NK cells are among the front line of protection from infected and abnormal cells as part of the ‘innate immune response’. They recognise ‘cell stress molecules’ on the surface of infected, old, injured and cancerous cells without the need for complex pre-stimulation signals of the adaptive immune system (eg, T cells).

Therapies 118

Therapies Clinical Trials Cell Biology Trials 118

Drug Target Review

FEBRUARY 28, 2024

Prior to that, Mr Ho was at New Leaf Venture Partners, a leading healthcare venture capital firm, where he launched and managed the public investments and cross-over portfolio, and served as its Public Investment Director from 2010 to 2014. gammadelta T cells link innate and adaptive immune responses. Cells 9(40):800 (2020).

Therapies 105

Therapies Engineering Molecular Biology Science 105

The Pharma Data

MAY 15, 2023

Bexsero is used as the comparator for the MenB immune responses induced by the MenABCWY vaccine in the trial, which is both the phase III trial for MenABCWY and confirmatory trial for Bexsero in the US. There are a total of 11 primary endpoints for the trial, five for MenABCWY and six for Bexsero.

Vaccine 40

Vaccine Immune Response Licensing Licensing 40

Drug Target Review

DECEMBER 28, 2023

These neoantigens are identified by T cells of the immune system as foreign proteins and thus trigger an immune response. Neoantigens are recognised as non-self and trigger an immune response.

Bioinformatics 105

Bioinformatics Immune Response DNA Vaccine 105

The Pharma Data

OCTOBER 14, 2020

Additionally, immunogenicity, duration of immune response and occurrence of symptomatic COVID-19 will be measured. Anti-tumor immunotherapy despite immunity to adenovirus using a novel adenoviral vector Ad5 [E1-, E2b-]-CEA. 2010 Jul;59(7):1131-5. Epub 2010 Apr 2. The Oncol, 25: 479-e899. PMID: 20361185.

Vaccine 40

Vaccine Trials FDA Clinical Trials 40

The Pharma Data

JANUARY 11, 2021

Xiaomin Fan, Founder, President and CEO of AvantGen, “Even with the recent Emergency Use Authorization of multiple vaccines, we believe there remains an urgent need for potent antibody therapies and prophylactics for immunocompromised patients who cannot mount an adequate immune response either to the vaccine or to subsequent viral infection.

Licensing 52

Licensing Licensing Therapies Engineering 52

Codon

JULY 27, 2023

a lower risk of immune responses. reports Cas9 proteins that can penetrate into the central nervous system without being packaged into an adeno-associated virus, all while causing a lower immune response than a prior version of the same technology. ” And a third paper (BOOM!)

Therapies 52

Therapies RNA DNA Engineering 52